| Title: |
Posaconazole and Amphotericin B Combination Therapy against Cryptococcus neoformans Infection |
| Authors: |
Barchiesi, Francesco; Spreghini, Elisabetta; Schimizzi, Anna M.; Maracci, Monia; Giannini, Daniele; Carle, Flavia; Scalise, Giorgio |
| Source: |
Antimicrobial Agents and Chemotherapy ; volume 48, issue 9, page 3312-3316 ; ISSN 0066-4804 1098-6596 |
| Publisher Information: |
American Society for Microbiology |
| Publication Year: |
2004 |
| Description: |
To investigate the effects of posaconazole (POS) and amphotericin B (AMB) combination therapy in cryptococcal infection, we established an experimental model of systemic cryptococcosis in CD1 mice by intravenous injection of three distinct clinical isolates of Cryptococcus neoformans . Therapy was started 24 h after the infection and continued for 10 consecutive days. POS was given at 3 and 10 mg/kg of body weight/day, while AMB was given at 0.3 mg/kg/day. Combination therapy consisted of POS given at a low (combo 3) or at a high (combo 10) dose plus AMB. Survival studies showed that combo 3 was significantly more effective than POS at 3 mg/kg for two isolates tested ( P value, ≤0.001), while combo 10 was significantly more effective than POS at 10 mg/kg for all three isolates ( P values ranging from |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1128/aac.48.9.3312-3316.2004 |
| DOI: |
10.1128/AAC.48.9.3312-3316.2004 |
| Availability: |
https://doi.org/10.1128/aac.48.9.3312-3316.2004; https://journals.asm.org/doi/pdf/10.1128/AAC.48.9.3312-3316.2004 |
| Rights: |
https://journals.asm.org/non-commercial-tdm-license |
| Accession Number: |
edsbas.B4BA09F0 |
| Database: |
BASE |